The word cancer still triggers fear. It still drives decisions.
For decades, the word 'cancer' has carried a weight that science is no longer certain it deserves for every diagnosis. As early detection has pushed survival rates for some cancers to 98 percent, medical experts in Ireland and beyond are asking whether language itself has become a source of harm — driving fear and overtreatment for conditions that may never threaten a life. The debate over renaming low-risk tumours is, at its heart, a question about how human beings live with uncertainty, and whether the words we inherit from a darker era of medicine still serve us.
- A single word — cancer — is triggering surgeries, radiation, and lasting harm for patients whose tumours carry less than a 5 percent chance of ever spreading.
- Specialists in prostate, breast, and thyroid cancer are sounding the alarm: the science of genomic testing can now distinguish dormant lesions from aggressive ones, but the terminology treats them as identical threats.
- Proposals to rename low-grade prostate lesions and ductal carcinoma in situ as 'pre-cancer' are gaining traction, yet pathologists warn that relabelling without education could create new confusion rather than clarity.
- A 2023 survey of prostate cancer patients revealed a community split almost perfectly in thirds — supporters, opponents, and the undecided — leaving the medical world without the patient consensus it needs to act.
- Until language catches up with knowledge, unnecessary psychological distress and overtreatment will remain the quiet cost of a vocabulary forged in an era when cancer almost always meant death.
A palliative care doctor who practised in the 1980s recalls a time when families begged physicians not to say the word cancer aloud — when euphemisms like 'neoplasm' or 'space-occupying lesion' were deployed to protect patients from the crushing weight of a single syllable. Decades later, that same doctor has watched survival rates for certain breast, prostate, testicular, and thyroid cancers climb as high as 98 percent. The disease has not changed so much as our ability to detect it has. But the language we use has not kept pace with the science.
The problem is that 'cancer' is not one thing. Some tumours carry less than a 5 percent chance of spreading over twenty years; others progress aggressively within one or two. A breast surgeon at the University of California, San Francisco, has argued that genomic testing now allows clinicians to measure these risks with real precision — and that definitions of cancer must evolve accordingly. The science has moved forward. The vocabulary has not.
The debate has crystallised around three diagnoses. Low-grade prostate cancer, scored as Gleason 6, results in tumour spread or death in fewer than 1 percent of men within 15 years, yet the cancer label routinely frightens patients into choosing surgery or radiation that can permanently diminish quality of life. Similarly, ductal carcinoma in situ — a breast diagnosis received by thousands of women each year — progresses to invasive cancer in only about 20 percent of cases, and that progression can take up to four decades. Most DCIS lesions never become dangerous, yet women are frequently overtreated.
Not everyone is persuaded that renaming is the answer. Pathologists caution that alternative terminology could confuse both patients and clinicians, and argue that better education about risk is the more responsible path. Patients themselves remain deeply divided: a 2023 survey found support, opposition, and indecision split almost equally among those diagnosed with low-grade prostate cancer.
What is not in dispute is that language shapes how people experience illness — what treatment they pursue, how they carry uncertainty, how they live. The old vocabulary was forged when cancer was nearly always fatal. The new science knows better. But until patients and doctors find common ground on new language, and until that language is genuinely understood, the fear the old word carries will continue to drive suffering that the disease itself need not.
A palliative care doctor practicing in the 1980s would never speak the word cancer directly to a patient. Families would intervene, insisting on euphemisms—neoplasm, mass, space-occupying lesion—anything but the C-word. The language itself carried weight that seemed to crush hope before treatment even began. Nearly four decades later, that doctor has watched the medical world transform. Early detection has rewritten survival odds. Certain breast cancers, prostate cancers, testicular cancers, thyroid cancers now carry survival rates as high as 98 percent when caught early. The disease hasn't changed as much as our ability to see it has. But the language we use to describe it hasn't kept pace.
This gap between what we know and what we say matters more than it might seem. The diseases we call cancer are not one thing. Some tumors have less than a 5 percent chance of spreading over two decades. Others have a 75 percent chance of progression within one or two years. They are fundamentally different diseases wearing the same name. Yet that name—cancer—still carries the weight it did in the 1980s. It still triggers fear. It still drives decisions.
A breast surgeon at the University of California, San Francisco, made the case plainly: our definitions of cancer need to evolve as our knowledge does. In the past, she argued, we couldn't reliably tell which lesions posed real danger. Now genomic tests can. We can measure risk with precision. We know which tumors will sit dormant for decades and which will spread aggressively. The science has moved forward. The language hasn't.
The debate has sharpened around three cancers in particular: prostate, breast, and thyroid. Consider low-grade prostate cancer, scored as Gleason 6. Fewer than 1 percent of men diagnosed with this condition experience tumor spread or death within 15 years. A group of North American specialists has proposed calling it pre-cancer instead. The reasoning is straightforward: the word cancer frightens men into choosing aggressive treatment—surgery, radiation—that may cause lasting harm to quality of life. For a disease that poses minimal threat, the cure becomes worse than the condition.
Breast cancer presents a similar puzzle. Thousands of women each year receive a diagnosis of ductal carcinoma in situ, or DCIS. The science shows that only about 20 percent of these cases will ever progress to invasive cancer, and that progression can take anywhere from five to 40 years. Most DCIS lesions never become dangerous. Yet women diagnosed with DCIS are routinely overtreated—with surgery, radiation, sometimes chemotherapy—despite the low actual risk. Calls have grown to reclassify DCIS as something other than cancer.
But renaming disease is not a simple matter of updating terminology. A counterargument from pathologists warns that alternative names could confuse patients and doctors alike. Better education, they suggest, is the answer—not relabeling. And patients themselves remain divided. A 2023 survey of 450 prostate cancer patients found that 35 percent supported reclassifying Gleason 6 as non-cancer. Another 35 percent opposed it. Thirty percent remained undecided. The medical community cannot move forward on this question without understanding what patients actually want.
Language shapes how people respond to illness. It influences whether they seek treatment, what treatment they choose, how they live with uncertainty. The old language—the language of the 1980s—treated all cancer as a death sentence. The new science knows better. But until patients and doctors agree on new language, and until that language is widely understood, the old fear will persist. The gap between what we know and what we say will continue to drive unnecessary suffering.
Citas Notables
In the past, it was not possible to reliably identify lesions with negligible risk. Today genomic tests inform our understanding of the risk and timing of recurrence, but we have yet to use them to change how we define cancer.— Laura Esserman, breast surgeon at University of California, San Francisco
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter what we call a tumor if we can measure its actual risk?
Because people don't live by numbers alone. When a doctor says the word cancer, something shifts in how a patient hears everything that follows. The word carries history—decades of it. Calling something cancer triggers a cascade of decisions, often before the patient has time to understand what the actual threat is.
So you're saying the label itself causes harm?
Not the label itself, but what the label makes people do. A man diagnosed with low-grade prostate cancer might choose surgery that damages his quality of life for years, when the tumor itself posed almost no threat. A woman with DCIS might undergo radiation for a lesion that would never have become dangerous. The word cancer justifies these treatments in people's minds.
But couldn't renaming it cause confusion? What if patients don't understand what pre-cancer means?
That's the real tension. You're right—just changing the name without education could backfire. A 2023 survey showed patients are split almost evenly on whether to rename low-grade prostate tumors. You can't move forward on something like this without agreement.
What changed between the 1980s and now?
Our ability to see inside tumors changed. Genomic tests can now tell us which lesions will sit dormant for decades and which will spread aggressively. We went from treating all cancers as the same threat to being able to measure actual risk. But our language didn't evolve with that knowledge.
If patients are divided, what happens next?
We stay stuck. The medical community can't unilaterally rename a disease. Patients have to understand why the change matters, and they have to agree it's worth making. Right now, that consensus doesn't exist.